Benefits
Multi-domain cognitive improvement
Nutricog users demonstrated significant improvements vs placebo across multiple cognitive domains: learning, memory, sustained attention, working memory, and executive function. These across-domain improvements come from a single manufacturer-funded proof-of-concept trial (n=100, 120 days) and need independent replication before broad-spectrum cognitive enhancement can be considered established.
Cognitive speed + accuracy simultaneously
In CANTAB testing, Nutricog subjects showed significantly improved Speed of Performance without a reduction in accuracy, meaning faster cognitive processing without the usual speed-accuracy tradeoff. In that single trial, gains in cognitive speed were seen alongside accuracy while multitasking; this is a single-trial finding, not an established general effect. Critical for real-world performance where both speed and accuracy matter (work, driving, complex decisions).
Fast 15-day onset
The earliest clinically significant benefits for Nutricog, memory and focus, were shown to start at just 15 days after commencing use. Most cognitive supplements require 4-12 weeks for measurable effects. The 15-day onset comes from that single manufacturer-funded proof-of-concept trial and has not been independently replicated.
Working memory and executive function
Working memory (the ability to hold and manipulate information) and executive function (planning, decision-making, multitasking) are the cognitive domains most relevant to everyday task performance. Both improved significantly with Nutricog. These higher-order cognitive functions are particularly valuable to maintain in adults aged 40-65 where natural age-related decline begins.
Validated with gold-standard cognitive instruments
Nutricog clinical effects were measured using RAVLT (Rey Auditory Verbal Learning Test) and CANTAB (Cambridge Neuropsychological Test Automated Battery), both well-established and validated instruments used in clinical neuropsychology research and pharmaceutical trials. Use of these instruments provides scientific credibility beyond consumer-perception surveys.
Health Canada approval for cognitive claims
PLT received a license from the Natural and Non-Prescription Health Products Directorate (NNHPD) of Health Canada to market Nutricog for cognitive health support in Canada. An NNHPD product license is a regulatory and marketing authorization that can be granted on a traditional-use or lower evidence tier; it permits the claim in Canada but is not independent validation of efficacy.
Quality-of-life multitasking improvements
The Nutricog clinical trial documented improved accuracy while multitasking, directly relevant to modern work and daily life demands. Multitasking under cognitive load is increasingly common in professional and personal contexts. Nutricog's positioning addresses real-world performance demands rather than abstract cognitive measures.
Mechanism of action
Gallic acid neuroprotective effects
Gallic acid (one of the Nutricog standardization markers) has documented neuroprotective and antioxidant effects in preclinical research. Reduces oxidative stress in neuronal cells and supports neurotransmitter function. Polyphenolic compounds like gallic acid cross the blood-brain barrier and act directly on central nervous system targets.
Ellagic acid antioxidant and anti-inflammatory
Ellagic acid (another standardization marker) has potent antioxidant and anti-inflammatory effects. Brain tissue is particularly vulnerable to oxidative damage due to high metabolic activity and lipid content. Antioxidant support helps preserve cognitive function by reducing neuronal oxidative stress that accumulates with age.
Amyrins (Boswellia triterpenes) cognitive effects
Amyrins (α- and β-amyrin) from Boswellia are pentacyclic triterpenes with documented neuroprotective, anti-inflammatory, and anxiolytic-like effects in preclinical research. The 5-LOX inhibition mechanism that supports Boswellia's joint health applications also extends to brain — reducing neuroinflammation that contributes to cognitive decline.
Multi-pathway cognitive support synergy
Nutricog combines Haritaki's polyphenolic compounds (gallic acid, ellagic acid) with Boswellia's terpenoid bioactives (amyrins) — different chemical classes addressing complementary cognitive mechanisms. The synergy explains the broad-spectrum effects across multiple cognitive domains vs single-mechanism cognitive supplements.
Neuroinflammation reduction
Both component botanicals reduce neuroinflammation through their respective anti-inflammatory pathways. Chronic low-grade neuroinflammation contributes to age-related cognitive decline. Reducing brain inflammation supports the structural and functional integrity of neurons over time — relevant to the cognitive improvements documented across the 40-65 trial population.
Clinical trials
Randomized double-blind placebo-controlled clinical trial assessing Nutricog for learning, memory, attention, working memory, and decision-making. 120-day intervention. Cognitive assessment via Rey Auditory Verbal Learning Test (RAVLT) and Cambridge Neuropsychological Test Automated Battery (CANTAB) — gold-standard validated cognitive instruments.
100 healthy male and female subjects aged 40-65 years. 120-day intervention.
Nutricog users demonstrated significant improvements vs placebo across multiple cognitive domains: learning, memory, sustained attention, working memory, and executive function. Several CANTAB tests showed significantly improved Speed of Performance without reduction in accuracy — improved cognitive speed concurrent with improved accuracy while multitasking. Earliest clinically significant benefits (memory and focus) started at just 15 days. This is a single-site, manufacturer-funded proof-of-concept RCT (PLT-employed lead author) that requires independent replication; it formed the basis of the Health Canada NNHPD marketing license.
Independent class evidence for both Nutricog component botanicals in cognitive applications: Terminalia chebula (Haritaki) has Ayurvedic precedent as a Medhya rasayana (cognitive enhancer) plus modern preclinical research; Boswellia serrata has extensive anti-inflammatory clinical trial data with emerging cognitive applications.
Various — preclinical and emerging clinical research on individual component botanicals.
Haritaki has documented neuroprotective effects via gallic acid and ellagic acid in preclinical models. Boswellia's 5-LOX inhibition and anti-inflammatory effects extend to brain tissue and neuroinflammation. No head-to-head trial has compared the combination against either botanical alone, so synergy beyond the individual components remains a hypothesis rather than a demonstrated effect; this component-class evidence is preclinical and emerging.